Gilead公司以7.8B美元收购Arcellx公司,以提振肿瘤管道,在混合分析师的看法和不确定性下,驱动库存接近52周的高水平。 Gilead acquires Arcellx for $7.8B to boost oncology pipeline, driving stock near 52-week high amid mixed analyst views and uncertainty.

Gilead Science同意以78亿美元购买生物技术公司Arcellx,每股现金115美元,加上与里程碑成果挂钩的5美元或有价值权利。 Gilead Sciences has agreed to acquire biotech firm Arcellx for $7.8 billion, offering $115 per share in cash plus a $5 contingent value right tied to milestone achievements. 这笔交易旨在支持Gilead的肿瘤管道与Arcellx的Anito-cel CAR T细胞疗法, 使得Arcellx的库存达到52周的最高水平, 近114美元。 The deal, aimed at bolstering Gilead’s oncology pipeline with Arcellx’s anito-cel CAR T-cell therapy, has driven Arcellx’s stock to a 52-week high near $114. 收购引起了投资者的乐观情绪,尽管分析师仍然意见不一,许多人由于近期的利得有限而将股票降级为持有股或中立股。 The acquisition has sparked investor optimism, though analysts remain divided, with many downgrading the stock to Hold or Neutral due to limited near-term upside. 关于交易公平性的法律调查和内部人士的销售增加了不确定性,而Arcellx准备公布2025年第四季度的收益,预计将出现亏损. Legal inquiries into the deal’s fairness and insider selling add uncertainty, while Arcellx prepares to release Q4 2025 earnings, expected to show a loss.